NDT Advance Access published online on October 18, 2005
Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfi231
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 University of North Carolina, Chapel Hill, NC, USA
* To whom correspondence should be addressed. Background. Chronic hepatitis C infection is prevalent among haemodialysis patients. The goal of our study was to determine the efficacy and safety of pegylated interferon Methods. We conducted a trial which randomized haemodialysis patients with chronic hepatitis C to 1.0 or 0.5 µg/kg of pegylated interferon Results. After 16 patients were enrolled, the study was terminated because of adverse events and modifications needed in the study design. Nine subjects were randomized to the 1.0 µg/kg group and seven subjects were randomized to the 0.5 µg/kg group. Serious adverse events requiring discontinuation of therapy occurred in five (56%) subjects in the 1.0 µg/kg group and in two (28%) subjects in the 0.5 µg/kg group (P = 0.36). The most common adverse events were hypertension and infection unrelated to neutropenia. Two (22%) subjects in the 1.0 µg/kg group, both genotype 1, had a sustained viral response, and none of the subjects in the 0.5 µg/kg group had a sustained viral response (P = 0.47). Five subjects in the 1.0 µg/kg group were able to complete 24 weeks or longer of therapy as per protocol and two (40%) were sustained responders. Conclusions. In our study group, pegylated interferon
Received April 6, 2005
Accepted September 28, 2005
Original Articles
Randomized trial of pegylated interferon
-2b monotherapy in haemodialysis patients with chronic hepatitis C
2 The Liver Institute at Methodist Dallas, Dallas, TX, USA
3 Mount Sinai School of Medicine, New York, NY, USA
4 Tulane University School of Medicine, New Orleans, LA, USA
Mark W. Russo, E-mail: Mark_Russo{at}med.unc.edu
Abstract 
-2b in haemodialysis patients with chronic hepatitis C.-2b subcutaneously, weekly for up to 48 weeks. End-points were sustained viral response and adverse events. Data were analysed as intention to treat and as intended per protocol.-2b was poorly tolerated and was associated with substantial side effects. Sustained response rates seen with pegylated interferon in our study do not appear to be better than rates reported for standard interferon -2b.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. E. Gordon, K. Uhlig, J. Lau, C. H. Schmid, A. S. Levey, and J. B. Wong Interferon for Hepatitis C Virus in Hemodialysis--an Individual Patient Meta-analysis of Factors Associated with Sustained Virological Response Clin. J. Am. Soc. Nephrol., September 1, 2009; 4(9): 1449 - 1458. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Covic, D. Abramowicz, A. Bruchfeld, G. Leroux-Roels, D. Samuel, W. van Biesen, C. Zoccali, F. Zoulim, R. Vanholder, and on behalf of the ERA-EDTA ERBP Advisory Board Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) hepatitis C guidelines: a European Renal Best Practice (ERBP) position statement Nephrol. Dial. Transplant., March 1, 2009; 24(3): 719 - 727. [Full Text] [PDF]
|
|
|
|
 |
|
 C-H Liu, C-C Liang, J-W Lin, S-I Chen, H-B Tsai, C-S Chang, P-H Hung, J-H Kao, C-J Liu, M-Y Lai, et al. Pegylated interferon {alpha}-2a versus standard interferon {alpha}-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study Gut, April 1, 2008; 57(4): 525 - 530. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. A. Terrault and D. B. Adey The Kidney Transplant Recipient with Hepatitis C Infection: Pre- and Posttransplantation Treatment Clin. J. Am. Soc. Nephrol., May 1, 2007; 2(3): 563 - 575. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Bruchfeld, K. Lindahl, O. Reichard, T. Carlsson, and R. Schvarcz Pegylated interferon and ribavirin in haemodialysis patients Nephrol. Dial. Transplant., May 1, 2006; 21(5): 1444 - 1445. [Full Text] [PDF]
|
|